View Post

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

In Clinical Trials by Barbara Jacoby

Provider: Business Wire From: apnews.com Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “ Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients” at the American Association for Cancer Research (AACR) Annual Meeting underway in Atlanta. The discussion …

View Post

Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Feasibility Study Intends to Quantify PRP’s Active Ingredients in Human Serum Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has initiated development of a bio-analytical assay intended to quantify the active ingredients of the company’s lead product candidate, PRP, in preparation …

View Post

Breast cancer drug approved for Australia

In Clinical Trials by Barbara Jacoby

By: AAP From: 9news.com.au Kate Harper wants to be around to watch her two young twin sons grow up. That’s why, after grappling with the feeling of helplessness that came with being diagnosed with breast cancer, she made a commitment. “I said right from the start – and my husband’s in agreement as well – that we would attack everything …

View Post

Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial

In Clinical Trials by Barbara Jacoby

From: businesswire.com Modra Pharmaceuticals B.V. (“Modra”) today announced that the first patients have been treated in its Phase IIa study in patients with recurrent or metastatic HER-2 negative breast cancer. The trial will evaluate the efficacy and safety of Modra’s lead product, ModraDoc006/r, a proprietary oral therapeutic based on the standard intravenous taxane chemotherapy, docetaxel. In addition to enabling patients …

View Post

SWOG’s 1501 study takes aim at the silo wall between cardiology and oncology

In Clinical Trials by Barbara Jacoby

By: Justin Floyd From: cancerletter.com Many have written and spoken about the goal of eliminating the effect of developing and delivering medical care in “silos.” Silos can simply be defined as medical or scientific environments functioning in parallel. They are independent and not often visible by those working in another silo. Silos often exist unintentionally, but have been a real …

View Post

Approval decision delay seen as positive for Karyopharm

In Clinical Trials by Barbara Jacoby

By: Andrew Dunn From: biopharmadive.com Dive Brief: The Food and Drug Administration pushed back the deadline for an approval decision by three months for Karyopharm Therapeutics’ experimental cancer drug — and investors celebrated the delay. The drugmaker gave the agency additional clinical information on selinexor’s accelerated approval application as a late-line treatment for relapsed refractory multiple myeloma, leading the FDA …

View Post

Findings About Children’s Solid Tumors Are Sparking New Therapies

In Clinical Trials by Barbara Jacoby

By: Beth Fand Incollingo From: curetoday.com Compared with solid tumors in adults — about which scientists are learning more and more — those that occur in children are mysteries. Not only are pediatric tumors rare, but they arise in developing tissues, making them difficult to study and treat. That’s where the Childhood Solid Tumor Network (CSTN), run by St. Jude …

View Post

Intraoperative radiotherapy viable for certain patients with breast cancer

In Clinical Trials by Barbara Jacoby

By: Jennifer Southall From: healio.com Intraoperative radiotherapy remains a viable option for patients with low-risk breast cancer, according to a presenter at Miami Breast Cancer Conference. “Intraoperative radiotherapy has been used for at least 10 to 15 years and, in appropriately selected patients, published results of the treatment are quite good,” Frank A. Vicini, MD, FACR, FABS, FASTRO, radiation oncologist …

View Post

Drug could alleviate side effects of chemo for breast cancer patients

In Clinical Trials by Barbara Jacoby

By: Mandy Erickson From: stanford.edu Stanford researchers have found a way to predict who will suffer heart problems from a common breast-cancer drug, as well as identified an FDA-approved medication that could mitigate those side effects. Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a …

View Post

Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

In Clinical Trials by Barbara Jacoby

Source: Atossa Genetics Inc. From: globenewswire.com Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the FDA has issued a “Safe to Proceed” letter under their “expanded access” program permitting the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, …